预约演示
Global Artificial Intelligence (AI) in Drug Discovery Market Report 2022: Growing Need to Control Drug Discovery & Development Costs is a Key Factor Driving the Adoption of AI in the Sector
2022-06-29
合作
DUBLIN, June 29, 2022 /PRNewswire/ -- The "Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024" report has been added to
ResearchAndMarkets.com's offering.
The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period. The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications and services. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growth at certain extent over the forecast period.
Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period
On the basis of offering, the AI in drug discovery market is bifurcated into software and services. the services segment expected to account for the largest market share of the global AI in drug discovery services market in 2022, and expected to grow fastest CAGR during the forecast period. The advantages and benefits associated with these services and the strong demand for AI services among end users are the key factors for the growth of this segment.
Machine learning technology segment accounted for the largest share of the global AI in drug discovery market
On the basis of technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. High adoption of machine learning technology among CRO, pharmaceutical and biotechnology companies and capability of these technologies to extract insights from data sets, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.
Pharmaceutical & biotechnology companies segment expected to hold the largest share of the market in 2022
On the basis of end user, the AI in drug discovery market is divided into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. In 2021, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market. On the other hand, research centers and academic & government institutes are expected to witness the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is the key growth factor of pharmaceutical and biotechnology end-user segment.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Growing Need to Control Drug Discovery & Development Costs is a Key Factor Driving the Adoption of AI in Drug Discovery Solutions
4.2 Services Segment to Witness the Highest Growth During the Forecast Period
4.3 Deep Learning Segment Accounted for the Largest Market Share in 2021
4.4 North America is the Fastest-Growing Regional Market for AI in Drug Discovery
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 18 Artificial Intelligence in Drug Discovery Market: Drivers, Restraints, Opportunities, and Challenges
5.2.1 Market Drivers
5.2.1.1 Growing Number of Cross-Industry Collaborations and Partnerships
5.2.1.2 Growing Need to Control Drug Discovery & Development Costs and Reduce Time Involved in Drug Development
5.2.1.3 Patent Expiry of Several Drugs
5.2.2 Market Restraints
5.2.2.1 Shortage of AI Workforce and Ambiguous Regulatory Guidelines for Medical Software
5.2.3 Market Opportunities
5.2.3.1 Growing Biotechnology Industry
5.2.3.2 Emerging Markets
5.2.3.3 Focus on Developing Human-Aware AI Systems
5.2.3.4 Growth in the Drugs and Biologics Market Despite the COVID-19 Pandemic
5.2.4 Market Challenges
5.2.4.1 Limited Availability of Data Sets
5.3 Value Chain Analysis
Figure 19 AI in Drug Discovery Market: Value Chain Analysis (2021)
5.4 Porter's Five Forces Analysiss
5.5 Ecosystem
5.6 Technology Analysis
5.7 Pricing Analysis
5.8 Business Models
5.9 Regulations
5.10 Conferences and Webinars
5.11 Case Study Analysis
6 Artificial Intelligence in Drug Discovery Market, by Offering
7 Artificial Intelligence in Drug Discovery Market, by Technology
8 Artificial Intelligence in Drug Discovery Market, by Application
9 Artificial Intelligence in Drug Discovery Market, by End-user
10 Artificial Intelligence in Drug Discovery Market, by Region
11 Competitive Landscape
Companies Mentioned
Benchsci
Benevolentai
Google
Nvidia
For more information about this report visit https://www.researchandmarkets.com/r/rr29jz
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。